Interleukin-12 Based Therapy for Inflammatory Diseases Download HRPP SOPs Clinical Trials Find a Researcher Tech ID: 95-05 Summary - Researchers from National Jewish Health have demonstrated in vivo in a murine model of asthma that administration of IL-12 is effective at substantially improving airway hyperresponsiveness. Potential Applications - Therapy for respiratory diseases such as asthma Advantages of Invention IL-12 is a natural substance therefore decreasing the possibility of toxic side effects IL-12 could be aerosolized State of Development - Treatment of a murine model of asthma with IL-12 decreases airway hyperresponsiveness by 80%. Further R&D Required - In vivo study in other animal models Patent - US patent # 5,674,483 Inventors - Charles Irvin, PhD and Yuan-Po Tu, MD, DVM Publication - Kodama et al. Clin Exp. Immunol. 2003 Feb 131(2):199-205 Licensing Status - This technology is available for licensing For Further Information, Contact: Emmanuel Hilaire, PhD Director Technology Transfer Office National Jewish Health 1400 Jackson Street, Room M206b Denver, CO 80206 Voice: (303) 398-1262 Fax: (303) 270-2352 HilaireE@njhealth.org